Eckert & Ziegler: Strong Underlying Growth in 2005
ECKERT & ZIEGLER Strahlen- und Medizintechnik AG / Dividend/Final Results
Ad-hoc-Announcement according to § 15 WpHG transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement.
Berlin, 29.03.2006 – The Supervisory Board of Eckert & Ziegler AG (ISIN DE0005659700) has at today’s meeting approved the 2005 Group financial statements showing a surplus after tax and minority interest of 0.51 EUR per share (2004: 1.09 EUR). At the same time it ratified the dividend proposal of the Executive Board of 0.15 EUR per share (2004: 0.25 EUR).
Adjusted to exclude start-up losses of 1.4 million EUR in connection with the entry into the new radio-pharmaceutical business, earnings before interest and tax rose by 24% from 3.4 million EUR to 4.3 million EUR (1.12 EUR and 1.38 EUR per share), earnings before interest, tax, depreciation and amortization by 14% from 7.2 million EUR to 8.2 million EUR (2.34 and 2.64 EUR per share).
The Berlin-Pankow-based technical medical concern recorded sales growth of 18% from 35.5 million EUR to 41.8 million EUR. Cash flow from operating activities climbed 40% from 2.5 million EUR to 3.5 million EUR (from 0.83 EUR to 1.14 EUR per share).
Further details on the 2005 financial statements will be made known at the accounts press conference on March 31, 2006.
Eckert & Ziegler AG, Karolin Riehle, Investor Relations Robert-Rössle-Str. 10, D-13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138
www.ezag.de
DGAP 29.03.2006
language: English
company: ECKERT & ZIEGLER Strahlen- und Medizintechnik AG Robert-Rössle-Str. 10
13125 Berlin Deutschland
phone: +49 (0)30 941 084-0
fax: +49 (0)30 941 084-112
email: karolin.riehle@ezag.de
WWW: www.ezag.de
ISIN: DE0005659700
WKN: 565970
indices:
stockmarkets: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin-Bremen, Hannover, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service